Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas

被引:200
作者
Diab, SG
Clark, GM
Osborne, CK
Libby, A
Allred, DC
Elledge, RM
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pathol, Div Med Oncol, San Antonio, TX 78284 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Pathol, Div Radiat Oncol, San Antonio, TX 78284 USA
[3] Wilford Hall USAF Med Ctr, Dept Pathol, Lackland AFB, TX 78236 USA
关键词
D O I
10.1200/JCO.1999.17.5.1442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To comprehensively characterize the clinical and biologic features of tubular and mucinous carcinomas in a large cohort of patients and to relate this to clinical outcome and management. Patients and Methods: The clinical and biologic features of 444 patients with tubular and 1,221 patients with mucinous carcinomas were compared with those of 43,587 patients with infiltrating ductal carcinoma, not otherwise specified (NOS), Disease-free survival (DFS) and overall survival (OS) for patients with tubular and mucinous carcinomas were compared with those of patients with NOS carcinomas and with age-matched sets from the general population, Results: Tubular and mucinous carcinomas were more likely to occur in older patients, be smaller in size (tubular only), have substantially less nodal involvement, be estrogen receptor- and progesterone receptor positive, have a lower S-phase fraction, be diploid, and be c-erbB-2- and epidermal growth factor receptor negative compared with NOS carcinomas. Axillary node involvement war a poor prognostic feature in mucinous but not tubular carcinomas. Mucinous carcinomas less than or equal to 1 cm had a less than or equal to 5% incidence of node involvement. The 5-year DFS and OS were 94% and 88% for tubular, 90% and 80% for mucinous, and 80% and 77% for NOS carcinoma, respectively (P <.001 for differences among all three types for both DFS and OS). The 5-year OS of females from the general population age-matched to the patients with tubular and mucinous carcinomas was 89% and 82%, respectively which is not different from the OS of patients with tubular or mucinous carcinomas. Conclusion: The biologic phenotype of tubular and mucinous carcinomas is quite favorable, Consistent with this observation, the survival of patients with tubular and mucinous carcinomas is similar to that of the general population. Systemic adjuvant therapy and node dissection may be avoided in many patients with these special types of carcinoma. J Clin Oncol 17:1442-1448. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:1442 / 1448
页数:7
相关论文
共 31 条
[1]   CORRELATION OF HER-2/NEU AMPLIFICATION WITH EXPRESSION AND WITH OTHER PROGNOSTIC FACTORS IN 1103 BREAST CANCERS [J].
CIOCCA, DR ;
FUJIMURA, FK ;
TANDON, AK ;
CLARK, GM ;
MARK, C ;
LEECHEN, GJ ;
POUNDS, GW ;
VENDELY, P ;
OWENS, MA ;
PANDIAN, MR ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (16) :1279-1282
[2]  
CLARK GM, 1993, CANCER-AM CANCER SOC, V71, P2157, DOI 10.1002/1097-0142(19930315)71:6+<2157::AID-CNCR2820711606>3.0.CO
[3]  
2-O
[4]   PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633
[5]   Telomerase activity and survival of patients with node-positive breast cancer [J].
Clark, GM ;
Osborne, CK ;
Levitt, D ;
Wu, F ;
Kim, NW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (24) :1874-1881
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   CORRELATION OF DNA FLOW CYTOMETRIC RESULTS AND OTHER PROGNOSTIC FACTORS IN PRIMARY BREAST-CANCER [J].
FEICHTER, GE ;
MUELLER, A ;
KAUFMANN, M ;
HAAG, D ;
BORN, IA ;
ABEL, U ;
KLINGA, K ;
KUBLI, F ;
GOERTTLER, K .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (06) :823-828
[8]  
HELIN HJ, 1989, CANCER, V63, P1761
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
KOMAKI K, 1988, CANCER, V61, P989, DOI 10.1002/1097-0142(19880301)61:5<989::AID-CNCR2820610522>3.0.CO